PE20140104A1 - Composiciones farmaceuticas que comprenden alisporivir - Google Patents

Composiciones farmaceuticas que comprenden alisporivir

Info

Publication number
PE20140104A1
PE20140104A1 PE2013001400A PE2013001400A PE20140104A1 PE 20140104 A1 PE20140104 A1 PE 20140104A1 PE 2013001400 A PE2013001400 A PE 2013001400A PE 2013001400 A PE2013001400 A PE 2013001400A PE 20140104 A1 PE20140104 A1 PE 20140104A1
Authority
PE
Peru
Prior art keywords
composition
alisporivir
weight
pharmaceutical compositions
amount
Prior art date
Application number
PE2013001400A
Other languages
English (en)
Inventor
Elisabete Goncalves
Karin Rapp
Bertrand Sutter
Frank Stowasser
Bjoern Trupp
Sebastian Chabaut
Julien Thorens
Original Assignee
Novartis Ag
Debiopharm Internat S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346477&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Debiopharm Internat S A filed Critical Novartis Ag
Publication of PE20140104A1 publication Critical patent/PE20140104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA CICLOSPORINA NO INMUNOSUPRESORA QUE INHIBE LA CICLOFILINA TAL COMO ALISPORIVIR EN UNA CANTIDAD DE 15 A 20% EN PESO DE LA COMPOSICION; B) UN COMPONENTE LIPOFILICO TAL COMO TRIGLICERIDOS DE CADENA MEDIANA, MONO-OLEATO DE SORBITAN, ACIDO OLEICO, ENTRE OTROS; C) UN TENSIOACTIVO TAL COMO HIDROXIESTEARATO DE GLICEROL MACROGOL, GLICERIDOS DE CAPRILOCAPROILO MACROGOL-8, CAPRILATO DE GLICERILO, ENTRE OTROS; D) UN COMPONENTE HIDROFILICO TAL COMO ETANOL, POLIETILENGLICOL, CITRATO DE TRIETILO, ENTRE OTROS; Y E) AGUA EN UNA CANTIDAD DE 2 A 15% EN PESO DE LA COMPOSICION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE INFECCIONES POR EL VIRUS DE LA HEPATITIS C
PE2013001400A 2010-12-13 2011-12-12 Composiciones farmaceuticas que comprenden alisporivir PE20140104A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42249910P 2010-12-13 2010-12-13
IB2011000319 2011-02-18
IB2011000653 2011-03-25

Publications (1)

Publication Number Publication Date
PE20140104A1 true PE20140104A1 (es) 2014-02-04

Family

ID=45346477

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001400A PE20140104A1 (es) 2010-12-13 2011-12-12 Composiciones farmaceuticas que comprenden alisporivir

Country Status (33)

Country Link
US (2) US20140005123A1 (es)
EP (1) EP2651396B1 (es)
JP (2) JP6259288B2 (es)
KR (1) KR101928589B1 (es)
CN (2) CN103282022A (es)
AR (1) AR084235A1 (es)
AU (3) AU2011344331A1 (es)
BR (1) BR112013014606A2 (es)
CA (1) CA2819167C (es)
CL (1) CL2013001684A1 (es)
CO (1) CO6761388A2 (es)
CY (1) CY1119468T1 (es)
DK (1) DK2651396T3 (es)
EC (1) ECSP13012679A (es)
ES (1) ES2643135T3 (es)
HR (1) HRP20171485T1 (es)
HU (1) HUE036784T2 (es)
IL (1) IL226554A (es)
JO (1) JO3337B1 (es)
LT (1) LT2651396T (es)
MA (1) MA34709B1 (es)
MX (1) MX351667B (es)
MY (1) MY165088A (es)
NZ (1) NZ610950A (es)
PE (1) PE20140104A1 (es)
PL (1) PL2651396T3 (es)
PT (1) PT2651396T (es)
RU (1) RU2639482C2 (es)
SG (2) SG10201509833YA (es)
SI (1) SI2651396T1 (es)
TW (1) TWI599368B (es)
WO (1) WO2012080176A2 (es)
ZA (1) ZA201303721B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101974665B1 (ko) 2010-12-13 2019-05-02 어레이 바이오파마 인크. 제ＩＩＩ형 수용체 티로신 키나제 억제제로서의 치환된 Ｎ-（１Ｈ-인다졸-４-일)이미다조［１,２-ａ］피리딘-３-카복스아마이드 화합물
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
FR2697040B1 (fr) 1992-10-21 1994-12-30 Ind Entreprise Elément de protection contre le bruit et son utilisation.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE504582C2 (sv) * 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
WO1999056727A2 (en) * 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
CN1218958C (zh) * 1998-07-01 2005-09-14 德比奥药物股份有限公司 活性范围改善的环孢菌素
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP4892486B2 (ja) * 2004-10-01 2012-03-07 デビオファーム ソシエテ アノニム Ｃ型肝炎感染の治療のための［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンの使用、及び当該［ｄ−ｍｅａｌａ］３−［ｅｔｖａｌ］４−シクロスポリンを含む医薬組成物
BRPI0519345A2 (pt) 2004-12-23 2009-01-20 Novartis Ag composiÇço para tratamento do hcv
GB0504950D0 (en) 2005-03-10 2005-04-20 Novartis Ag Organic compositions
WO2010052559A1 (en) 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير

Also Published As

Publication number Publication date
SG190894A1 (en) 2013-07-31
JP6259288B2 (ja) 2018-01-10
WO2012080176A3 (en) 2012-08-09
KR20140018858A (ko) 2014-02-13
MY165088A (en) 2018-02-28
WO2012080176A2 (en) 2012-06-21
IL226554A (en) 2017-12-31
US10188696B2 (en) 2019-01-29
AU2016201053A1 (en) 2016-03-10
ECSP13012679A (es) 2013-08-30
PL2651396T3 (pl) 2017-12-29
JP2014503520A (ja) 2014-02-13
ZA201303721B (en) 2014-04-30
CO6761388A2 (es) 2013-09-30
CL2013001684A1 (es) 2014-01-10
EP2651396A2 (en) 2013-10-23
AR084235A1 (es) 2013-05-02
JO3337B1 (ar) 2019-03-13
NZ610950A (en) 2015-07-31
CN103282022A (zh) 2013-09-04
DK2651396T3 (en) 2017-10-23
ES2643135T3 (es) 2017-11-21
SI2651396T1 (sl) 2017-11-30
AU2017245296A1 (en) 2017-11-02
CA2819167C (en) 2019-12-31
PT2651396T (pt) 2017-10-18
CN105125489B (zh) 2019-04-16
MX351667B (es) 2017-10-24
JP2018027949A (ja) 2018-02-22
MX2013006525A (es) 2013-08-01
LT2651396T (lt) 2017-09-25
HUE036784T2 (hu) 2018-08-28
SG10201509833YA (en) 2016-01-28
AU2011344331A1 (en) 2013-07-11
RU2639482C2 (ru) 2017-12-21
CY1119468T1 (el) 2018-03-07
US20160367624A1 (en) 2016-12-22
KR101928589B1 (ko) 2018-12-12
EP2651396B1 (en) 2017-07-12
RU2013132543A (ru) 2015-01-20
MA34709B1 (fr) 2013-12-03
AU2016201053B2 (en) 2017-07-13
TW201306859A (zh) 2013-02-16
CA2819167A1 (en) 2012-06-21
BR112013014606A2 (pt) 2017-06-06
TWI599368B (zh) 2017-09-21
CN105125489A (zh) 2015-12-09
HRP20171485T1 (hr) 2017-11-17
US20140005123A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
EA201201031A1 (ru) Ингибиторы вируса гепатита с
PE20140104A1 (es) Composiciones farmaceuticas que comprenden alisporivir
ECSP12011845A (es) Nuevos inhibidores macrocíclicos de la replicación
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
PE20141056A1 (es) Metodos para el tratamiento de vhc
PE20120602A1 (es) ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
RU2013121788A (ru) Ингибиторы репликации вич
PE20120322A1 (es) Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
CO6400183A2 (es) Formas de dosificación oral de bendamustina
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
AR106776A1 (es) Composiciones de cuidado oral
PE20140255A1 (es) Tableta dispersable en forma oral
ECSP11011199A (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
CO6640318A2 (es) Formas de dosificación oral de bendamustina
EA201170287A1 (ru) Фармацевтические композиции и способы их стабилизации

Legal Events

Date Code Title Description
FG Grant, registration